Synlogic
once a pioneer of "living drug" bacterial therapeutics engineered with gut-restricted kill switches, discontinued its Synpheny-3 Phase 3 trial for phenylketonuria after an internal review suggested it would not meet its primary endpoint;…
- Country
- United States
- Ticker
- SYBX
living-drugs
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsfdaepamoa-china
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Intelligent genetic switches (kill switches) | genome-engineering | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.